Data cannot be made publicly available as the terms and conditions of this collaboration restricted the availability of original data as follows: 1) Only certain categories of people are permitted to access and use the "Analytical Tool" (that is, the software processing input data and generating output data for providing benchmarking to each hospital for quality improvements). These are defined as: "Permitted Users" means the Participant's directors, employees and independent contractors who are authorised by the Participant to access and use the Analytical Tool for the purposes provided in this Agreement. 2) Access to and use of the Analytical Tool itself is granted only for the "Term" and for specific purposes, being "accessing and viewing the Output Data and to use the Output Data for the purpose of participating in and reviewing the results of the Project". The restriction is related to the contract between the participating hospitals and Dr. Foster Telstra Health. There it was specified who has access to the data and that they may not be shared with other people as described above. Other researchers can request access to the data as long as they fulfil the requirements of the contract. Contracting the responsible person in each individual hospital is possible, but the authors cannot guarantee that each hospital will provide the data. This is the responsibility of each hospital. It would be all administrative data of the according years in the participating hospitals. The data are owned by the participating hospitals. A list of participating hospitals, and their contact information is included in the supporting information. List of participating hospitals please see [S2 Table](#pone.0233457.s002){ref-type="supplementary-material"}.

Introduction {#sec005}
============

Chronic diseases are increasingly prevalent in Western countries due to population aging and better treatment of underlying conditions. Once hospitalised, the chance for another hospitalisation increases sharply. The wide variation in readmission rates suggests that a significant proportion is avoidable \[[@pone.0233457.ref001]\]. The US Hospital Readmissions Reduction Program requires Centers for Medicare and Medicaid Services to reduce payments to hospitals with excess readmissions \[[@pone.0233457.ref002]\].

Readmissions pose a significant burden to patients and healthcare systems as they create significant mortality and morbidity \[[@pone.0233457.ref003]\]. The latter is not only important regarding well-being, but also has an important economic impact in form of costly hospitalisations \[[@pone.0233457.ref004]\]. Therefore, one important aim in treating chronic diseases is to prevent readmissions. The high risk of readmission has been shown for different chronic diseases \[[@pone.0233457.ref005]--[@pone.0233457.ref007]\] and after diverse interventions such as hip replacement, hip fracture, otolaryngology, bypass or general surgery \[[@pone.0233457.ref008]--[@pone.0233457.ref012]\]. The reasons for readmission after an intervention are often not primarily related to the intervention itself, but to the underlying comorbid conditions. Thus, chronic diseases may play an important role in readmission risk, independently of the reason for the initial hospitalisation \[[@pone.0233457.ref013]\].

Chronic diseases usually do not occur in isolation. Most patients with chronic disease have multiple diseases \[[@pone.0233457.ref014]\]. They may influence each other, and treatment for one disease may adversely impact the other. Hospital quality also impacts readmission rates \[[@pone.0233457.ref015]\]. Therefore, the pattern of readmissions may be very complex. Because of the interactions between disease and treatment, knowing patterns of readmissions related to different chronic diseases may improve the understanding of this important problem and reveal new treatment modalities for these patients. Unfortunately, most previous studies focused on single disease presentation at index hospitalisation and did not investigate the interplay between different diseases \[[@pone.0233457.ref016]\].

Therefore, we aimed to investigate reasons for readmission in patients with an index hospitalisation for multiple chronic conditions and three acute diseases usually related to an underlying chronic condition. We used data from an international dataset created from hospitals around the world through the Global Comparators project \[[@pone.0233457.ref017]\]. Our hypothesis was that reasons for readmission are often different from the index hospitalisation, irrespective of the underlying condition, and that this complexity increases with age and comorbidities. We also wanted to determine if the result changed over time, to what extent the results were influenced by in-hospital mortality, and if there were country specific differences.

Methods {#sec006}
=======

We collected electronic inpatient records from administrative discharge data provided by each of the 21 participating hospitals (eight from USA, five from UK, four from Australia, one each from Belgium, Denmark, Italy and the Netherlands; the latter four are combined as European centres; [S1 Table](#pone.0233457.s001){ref-type="supplementary-material"}), integrated into a uniform dataset as described elsewhere \[[@pone.0233457.ref017]\]. Institutional regulatory boards waived the requirement of Informed consent by patients and data were fully anonymised for the purpose of this analysis. For the present analysis, we used data from six complete calendar years, 2009--2014. All hospitals were major teaching hospitals. We excluded data before (i.e. 2007--2008) and after (i.e. 2015 and 2016) this period because many centres did not provide data for those periods to avoid selection bias. Between 2011--2013, complete data are available in all centres; in the two years before data from four hospitals (three in USA, one European) and in 2014 data from two UK hospitals were missing. Some hospitals reported in a previous publication \[[@pone.0233457.ref018]\] were excluded due to data quality issues, some missing codes and linkage issues from one year to the next.

We included records containing information on age, sex, country, principal diagnosis code (International Classification of Diseases, ICD-9 or ICD-10 \[ICD-10_CM, ICD-10 AM\]), Clinical Classification Software (CCS) group (Agency for Healthcare Quality and Research's CCS groups (AHRQ CCS)) as described previously, \[[@pone.0233457.ref017]\] admission date, discharge date (date of death if admission ended in death) and in-hospital death. Each record was assigned a comorbidity score according to a modified version of the Elixhauser index \[[@pone.0233457.ref019]\], which is based on 32 conditions identified by secondary diagnoses codes \[[@pone.0233457.ref020]\]. Admissions were assigned to one of 259 diagnostic groups based on the primary diagnosis field (AHRQ CCS). Both bespoke chronic diseases (ICD-classification) and CCS codes were used to define the following chronic conditions as index hospitalisations: heart failure (HF); atrial fibrillation (AF); myocardial infarction (AMI); hypertension; stroke; chronic obstructive pulmonary disease (COPD); bacterial pneumonia; diabetes mellitus; chronic renal disease; anaemia; arthritis and other cardiovascular disease (see [S2 Table](#pone.0233457.s002){ref-type="supplementary-material"}). We included three acute conditions, i.e. stroke, AMI and bacterial pneumonia; AMI because it represents the most important event of an important underlying chronic condition, i.e. coronary artery disease, and pneumonia because it is often related to underlying chronic lung diseases, particularly COPD.

We excluded records corresponding to planned day-cases. Due to the difficulty in some countries in distinguishing patients admitted for observation only from those admitted as inpatients, we also excluded short-term emergency admissions with length of stay (LOS) less than two nights and no surgery.

Rates and reasons for readmissions within 30 days were analysed, focusing on the comparison between similar and different reasons for readmission compared with the index hospitalisation. Descriptive comparisons were made for each of the above-mentioned diseases. For a better illustration, Sankey diagrams are used to show the readmission patterns for each of these conditions \[[@pone.0233457.ref021]\]. Readmissions could only be identified when readmission was to the same hospital. For the analysis investigating readmission rates, in-hospital deaths were not considered. We allowed for a three-month window at the end of the time-period to ensure capturing the majority of readmissions for each hospital. For consistency across countries, readmissions with discharge after a three-month window were not counted, which accounted for \<0.5% of the cases.

We further compared the readmission distributions for each of the 12 diseases, given by the proportion of readmissions to each of the 12 conditions or any CCS group. We calculated the Hellinger distance \[[@pone.0233457.ref022]\] between each pair, to identify clusters within the readmission patterns of the 12 diseases. By definition, the Hellinger distance is between zero and one, where zero means that patterns are identical, the larger the distance the more dissimilar the patterns.

To investigate the proportion of readmissions with similar versus different diseases we performed logistic regression with the outcome: readmission with the same versus any other condition. The model was adjusted for age, sex, year of discharge, comorbidity score, country, chronic condition and LOS. We applied a square root transformation to LOS as data are highly skewed to the right. Variables were considered significant when p\<0.05. All data analyses were done using R, v. 3.4.2 \[[@pone.0233457.ref023]\].

Results {#sec007}
=======

Out of 4,901,586 admissions, 866,502 (17.7%) were due to the 12 bespoke conditions as primary diagnosis (UK n = 207,748, 15.4%; continental Europe n = 187,182, 17.7%; Australia n = 161,171, 18.0%; USA n = 310,401, 19.4% USA). The patient characteristics are shown in [Table 1](#pone.0233457.t001){ref-type="table"}. Patients in the USA were younger compared with the other countries, had a shorter LOS and more co-morbidities recorded. There were significant differences in baseline characteristics between the different conditions. Average LOS varied by a factor of almost three between the different conditions and differed between countries ([Table 1](#pone.0233457.t001){ref-type="table"}). [Table 2](#pone.0233457.t002){ref-type="table"} shows the most common CCS groups / chronic conditions by number of admissions, indicating that the selected conditions are among the most important reasons for hospitalisation. [Fig 1](#pone.0233457.g001){ref-type="fig"} provides an overview of the reasons of admission in the different countries over time.

![Proportion of admissions over time for the 12 chronic conditions in different countries.\
Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g001){#pone.0233457.g001}

10.1371/journal.pone.0233457.t001

###### Patient characteristics.

![](pone.0233457.t001){#pone.0233457.t001g}

                             Average age   Average number of comorbidities   \% male   Average length of stay (LOS)   Median LOS
  -------------------------- ------------- --------------------------------- --------- ------------------------------ ------------
  **Overall**                65.4          2.29                              56.6      7.5                            4
  **Country**                                                                                                          
  Australia                  68.4          1.81                              58.1      8.5                            4
  Continental Europe         66.6          1.38                              57.8      7.7                            5
  England                    66.3          1.98                              58.6      9.3                            5
  USA                        62.5          3.30                              53.6      5.8                            4
  **Chronic condition**                                                                                                
      AF                     65.6          1.80                              57.0      4.5                            3
      AMI                    66.9          2.26                              69.9      5.7                            3
      Anemia                 52.4          1.68                              45.3      6.2                            4
      Arthritis              63.9          1.46                              42.1      4.3                            3
      COPD                   68.6          1.77                              51.0      7.6                            5
      Diabetes               52.4          2.20                              56.5      7.8                            4
      Heart failure          70.6          3.57                              55.5      8.9                            6
      Hypertension           62.4          1.49                              43.3      4.9                            3
      Other cardiovascular   67.7          2.10                              60.9      8.5                            4
      Pneumonia              64.2          2.31                              53.3      8.9                            6
      Renal failure          63.1          3.06                              56.7      8.5                            5
      Stroke                 68.5          2.53                              50.3      12.7                           6

Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease

10.1371/journal.pone.0233457.t002

###### Most common CCS groups and chronic conditions as primary cause of initial hospitalization.

![](pone.0233457.t002){#pone.0233457.t002g}

  Condition group                                                                     Volume   Percentage
  ----------------------------------------------------------------------------------- -------- ------------
  CCS group Liveborn                                                                  231377   4.72%
  Chronic condition AMI                                                               175437   3.58%
  CCS group Complication of device, implant or graft                                  115533   2.36%
  Chronic condition Pneumonia                                                         97496    1.99%
  CCS group Other complications of birth, puerperium affecting management of mother   90551    1.85%
  Chronic condition Stroke                                                            86189    1.76%
  Chronic condition Heart failure                                                     84963    1.73%
  Chronic condition AF                                                                82723    1.69%
  CCS group Complications of surgical procedures or medical care                      80353    1.64%
  CCS group Spondylosis, intervertebral disc disorders, other back problems           75086    1.53%
  Chronic condition Other cardiovascular disease                                      72414    1.48%
  CCS group Other nervous system disorders                                            66199    1.35%
  CCS group Biliary tract disease                                                     65289    1.33%
  Chronic condition COPD                                                              63450    1.29%
  CCS group Secondary malignancies                                                    61933    1.26%
  CCS group Urinary tract infections                                                  61488    1.25%
  CCS group Residual codes, unclassified                                              60878    1.24%
  Chronic condition Arthritis                                                         59969    1.22%
  CCS group Septicemia (except in labour)                                             59506    1.21%
  Chronic condition Chronic renal failure                                             57209    1.17%
  CCS group Skin and subcutaneous tissue infections                                   56959    1.16%
  CCS group Trauma to perineum and vulva                                              52616    1.07%
  CCS group Normal pregnancy and/or delivery                                          51040    1.04%
  CCS group Maintenance chemotherapy, radiotherapy                                    50700    1.03%
  CCS group Fracture of upper limb                                                    49437    1.01%
  CCS group Foetal distress and abnormal forces of labour                             48947    1.00%
  CCS group Rehabilitation care, fitting of prostheses, and adjustment of devices     46808    .95%
  CCS group Fracture of lower limb                                                    46628    .95%
  CCS group Other and unspecified benign neoplasm                                     45375    .93%
  CCS group Epilepsy, convulsions                                                     44791    .91%
  CCS group Osteoarthritis                                                            44689    .91%
  CCS group Abdominal hernia                                                          44214    .90%
  CCS group Other connective tissue disease                                           44197    .90%
  CCS group Other complications of pregnancy                                          44190    .90%
  Chronic condition Diabetes                                                          41136    .84%
  Chronic condition Anemia                                                            38163    .78%
  CCS group Heart valve disorders                                                     38089    .78%
  CCS group Affective disorders                                                       37311    .76%
  CCS group Fracture of neck of femur (hip)                                           37177    .76%
  CCS group Other fractures                                                           36657    .75%
  CCS group Appendicitis and other appendiceal conditions                             36167    .74%
  CCS group Other gastrointestinal disorders                                          34775    .71%
  CCS group Other perinatal conditions                                                34214    .70%
  CCS group Crushing injury or internal injury                                        33283    .68%
  CCS group Other upper respiratory disease                                           32306    .66%
  CCS group Cancer of bronchus, lung                                                  31956    .65%
  CCS group Gastrointestinal haemorrhage                                              31834    .65%
  CCS group Abdominal pain                                                            31453    .64%
  CCS group Cancer of breast                                                          31219    .64%
  CCS group Intracranial injury                                                       29403    .60%
  CCS group Intestinal obstruction without hernia                                     29162    .59%
  CCS group Fluid and electrolyte disorders                                           28882    .59%
  CCS group Other nutritional, endocrine, and metabolic disorders                     28152    .57%
  CCS group Intestinal infection                                                      27751    .57%
  CCS group Pancreatic disorders (not diabetes)                                       27448    .56%
  CCS group Calculus of urinary tract                                                 27337    .56%
  CCS group Acute bronchitis                                                          27261    .56%
  CCS group Nonspecific chest pain                                                    26377    .54%
  CCS group Other screening for suspected conditions                                  24198    .49%
  CCS group Asthma                                                                    24019    .49%

Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; CCS Clinical Classification Software (definition see [Methods](#sec006){ref-type="sec"}); COPD chronic obstructive pulmonary disease

Overall, 43,573 (5.0%) patients died in-hospital with significant differences between the conditions ([Table 3](#pone.0233457.t003){ref-type="table"}), leaving 822,929 admissions for readmission analysis. Of those, 87,452 (10.6%) had an emergency readmission within 30 days ([Table 3](#pone.0233457.t003){ref-type="table"}). Readmission rate was highest in the USA (19.0%), followed by Australia (17.6%), England (16.5%) and continental Europe (14.6%). No major changes were seen over time, but there were some differences between the countries ([Fig 2](#pone.0233457.g002){ref-type="fig"}). Apart from anaemia and COPD, more than half of the readmissions were due to diseases other than the initial hospitalisation ([Table 3](#pone.0233457.t003){ref-type="table"}). Interestingly, average LOS for the initial admission was comparable between patients that were not readmitted and were readmitted with the same condition in all 12 conditions but significantly longer in those readmitted due to another condition ([Fig 3](#pone.0233457.g003){ref-type="fig"}). Though the extent of this increase in LOS varied, it was seen in basically all conditions.

![Proportion of readmissions over time in different countries for each of the 12 chronic conditions.\
Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g002){#pone.0233457.g002}

![**Length of stay (LOS) for the index hospitalisation of the chronic conditions in those that were not readmitted (grey), readmitted with the same condition (orange) and with another condition (blue).** Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g003){#pone.0233457.g003}

10.1371/journal.pone.0233457.t003

###### Rate of in-hospital mortality, 30-day readmissions, percentage of conditions of readmissions and total events (combination of readmissions and deaths) in relation to the reason for index hospitalisation.
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                                                                               \% of all readmissions                             
  ---------------------- --------- -------- ------- --------- ---------------- ------------------------ ------- ------- --------- -------
  Pneumonia              97,496    9,959    10.2%   87,537    11,507 (13.1%)   24.1%                    20.5%   55.4%   21,466    22.0%
  Heart failure          84,963    5,078    6.0%    79,885    13,333 (16.7%)   42.1%                    22.7%   35.2%   18,411    21.7%
  COPD                   63,450    2,456    3.9%    60,994    11,231 (18.4%)   51.9%                    17.9%   30.2%   13,687    21.8%
  Renal failure          57,209    3,101    5.4%    54,108    8,579 (15.9%)    18.4%                    18.8%   62.8%   11,680    20.4%
  Anemia                 38,163    568      1.5%    37,595    6,818 (18.1%)    52.9%                    10.2%   36.9%   7,386     19.4%
  Stroke                 86,189    11,105   12.9%   75,084    5,134 (6.8%)     26.8%                    14.8%   58.4%   16,239    18.8%
  Diabetes               41,136    580      1.4%    40,556    5,310 (13.1%)    42.6%                    13.8%   43.6%   5,890     14.3%
  Other cardiovascular   72,414    3,894    5.4%    68,520    6,433 (9.4%)     21.2%                    17.6%   61.2%   10,327    14.3%
  Hypertension           7,353     63       0.9%    7,290     620 (8.5%)       22.9%                    35.7%   41.4%   683       9.3%
  AMI                    175,437   5,374    3.1%    170,063   10,659 (6.3%)    27.4%                    27.4%   45.2%   16,033    9.1%
  AF                     82,723    1,326    1.6%    81,397    6,169 (7.6%)     32.2%                    26.3%   41.5%   7,495     9.1%
  Arthritis              59,969    69       0.1%    59,900    1,659 (2.8%)     10.9%                    17.4%   71.7%   1,728     2.9%
  Total                  866,502   43,573   5.0%    822,929   87,452 (10.6%)   33.9%                    19.9%   46.2%   131,025   15.1%

Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease

Overall, the average and median time to readmission did not differ between readmission due to the same or another condition ([Fig 4](#pone.0233457.g004){ref-type="fig"}). The median time until readmission was 11 days for both the same and another condition. Average time until readmission did not vary much between the 12 conditions with only hypertension and stroke having considerably shorter time to readmission for the same condition ([Fig 4](#pone.0233457.g004){ref-type="fig"}).

![Average time to readmission overall and per original condition, depending on if readmission was due to the same or another condition.\
Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g004){#pone.0233457.g004}

The specific reasons for readmission of the 12 conditions are depicted in [Fig 5A and 5B](#pone.0233457.g005){ref-type="fig"}. These figures show that the causes of readmissions for a reason other than the same condition are diverse for all conditions. Regarding other causes than the 12 conditions, complications related to procedures / care during the initial hospitalisation or related to devices / implants are the most common ones, followed by infections. However, there was a large diversity of other causes ([Fig 5B](#pone.0233457.g005){ref-type="fig"}).

![**Link between original condition of admission (left side) and cause of readmission (right side) for each chronic condition.** B provides information about all other causes in A. These figures (Supporting information: Interacting [Fig 1A and 1B](#pone.0233457.g001){ref-type="fig"}) can be found online by clicking on the figures to provide a dynamic depiction of the different causes of readmission for each chronic condition. Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g005){#pone.0233457.g005}

In addition to readmission for the same reason (Hellinger distance = 0), several weak clusters (light orange) were identified, such as pneumonia and COPD; HF, MI and AF; other cardiovascular, chronic renal failure and arthritis ([Fig 6](#pone.0233457.g006){ref-type="fig"}). COPD and anaemia had the greatest distance from each other, and anaemia was far away from all other conditions. Anaemia was also the condition with the highest proportion of readmissions with the same condition ([Table 3](#pone.0233457.t003){ref-type="table"}).

![Readmission pattern for each of the chronic conditions (Hellinger distance matrix).\
Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g006){#pone.0233457.g006}

Various factors made readmission with the same condition more or less likely ([Table 4](#pone.0233457.t004){ref-type="table"}). Patients with the initial hospitalisation due to COPD, HF, anaemia, and diabetes were most likely admitted with the same condition. In the USA, readmission due to the same cause was less likely. The chance of being readmitted due to the same cause was increased in male patients, with lower age, with less co-morbidities, at the beginning of the study period and with shorter LOS during initial admission. The effect of age was particularly evident in patients aged \<60 years, and less evident at older ages, but the effect of age was not the same for all chronic conditions ([Fig 7](#pone.0233457.g007){ref-type="fig"}).

![Readmission rates with the same condition by age for each of the chronic conditions.\
Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease.](pone.0233457.g007){#pone.0233457.g007}

10.1371/journal.pone.0233457.t004

###### Odds ratios (OR) of multivariable regression for probability of readmission with the same condition as initial hospitalisation.
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                                            OR (95%-confidence interval)
  ----------------------------------------- ----------------------------------------------------------------
  Chronic Condition: Arthritis              1.000 (Reference)
  Chronic Condition: AF                     4.257[\*\*\*](#t004fn003){ref-type="table-fn"} (3.610, 5.021)
  Chronic Condition: AMI                    3.366[\*\*\*](#t004fn003){ref-type="table-fn"} (2.863, 3.958)
  Chronic Condition: Anaemia                7.328[\*\*\*](#t004fn003){ref-type="table-fn"} (6.219, 8.634)
  Chronic Condition: Renal failure          2.021[\*\*\*](#t004fn003){ref-type="table-fn"} (1.713, 2.386)
  Chronic Condition: COPD                   9.460[\*\*\*](#t004fn003){ref-type="table-fn"} (8.057, 11.109)
  Chronic Condition: Diabetes               5.468[\*\*\*](#t004fn003){ref-type="table-fn"} (4.632, 6.454)
  Chronic Condition: Heart failure          7.774[\*\*\*](#t004fn003){ref-type="table-fn"} (6.624, 9.122)
  Chronic Condition: Hypertension           2.485[\*\*\*](#t004fn003){ref-type="table-fn"} (1.943, 3.179)
  Chronic Condition: Other cardiovascular   2.397[\*\*\*](#t004fn003){ref-type="table-fn"} (2.027, 2.834)
  Chronic Condition: Pneumonia              2.934[\*\*\*](#t004fn003){ref-type="table-fn"} (2.494, 3.451)
  Chronic Condition: Stroke                 3.852[\*\*\*](#t004fn003){ref-type="table-fn"} (3.255, 4.559)
  Country: Australia                        1.000 (Reference)
  Country: England                          .968 (.922, 1.017)
  Country: Continental Europe               .979 (.935, 1.026)
  Country: USA                              .728[\*\*\*](#t004fn003){ref-type="table-fn"} (.698, .760)
  Female                                    .954[\*\*\*](#t004fn003){ref-type="table-fn"} (.926, .983)
  Age                                       .984[\*\*\*](#t004fn003){ref-type="table-fn"} (.983, .984)
  Comorbidity score                         .986[\*\*\*](#t004fn003){ref-type="table-fn"} (.985, .987)
  Year                                      .987[\*\*\*](#t004fn003){ref-type="table-fn"} (.978, .996)
  LOS (sqrt days)                           .870[\*\*\*](#t004fn003){ref-type="table-fn"} (.859, .881)
  C-statistic                               .695
  Observations                              87,452

\*p \< .1

\*\*p \< .05

\*\*\*p \< .01

Abbreviations: AF atrial fibrillation; AMI acute myocardial infarction; COPD chronic obstructive pulmonary disease

Discussion {#sec008}
==========

In this large multinational cohort of hospital admissions with various chronic conditions, readmissions within 30 days were common and the reason for readmission differed from the index admission in more than 50% of the cases. This is true among all participating countries and all conditions investigated, despite significant differences between countries and conditions. This is the most comprehensive study reporting readmission rates for a broad spectrum of chronic conditions in different countries. It highlights the extent and the complexity of the problem as well as the need for focus not only on the disease that caused the initial hospitalisation, but also on other frequently related conditions. This stresses the need to approach readmission prevention from a holistic consideration of all the patient's comorbidities.

When a person-centred approach is to the whole patient, readmission rates may be reduced \[[@pone.0233457.ref024]\]. It is surprising that there is not more focus on this, given that the number of comorbidities is associated with increased mortality and an increased readmission rate, both early and later after discharge \[[@pone.0233457.ref025], [@pone.0233457.ref026]\]. If comorbidities primarily increase the susceptibility of deteriorating with the same condition or simply increase the risk of manifestation of other diseases has not yet been properly investigated, but comorbidities clearly increase the complexity of the condition \[[@pone.0233457.ref027]\]. In patients with an index hospitalisation of COPD, readmission due to other causes was accompanied with significantly higher mortality than readmission due to COPD \[[@pone.0233457.ref028]\]. Therefore, the patterns accompanied with the highest risks of readmission should be more adequately investigated and addressed to prevent early events. Readmission is a multifactorial phenomenon constructed as a quality measure in many countries, with contributions from underlying disease and comorbidities (as found in our data), patient factors (e.g. psychosocial resilience), healthcare worker effects, environmental and social determinants of health, organisational and healthcare system factors \[[@pone.0233457.ref015], [@pone.0233457.ref016], [@pone.0233457.ref029], [@pone.0233457.ref030]\]. In addition, the organisation of care post-discharge, such as timeliness of follow-up, coordination with primary care, and quality of medication management may significantly influence readmission rate \[[@pone.0233457.ref031], [@pone.0233457.ref032]\]. Preventable readmission is what we should be focusing on, but consensus on how to achieve this is poor \[[@pone.0233457.ref033]\]. Our data suggest that the focus on and treatment of the index condition only, as currently done in many institutions is not sufficient. Thus, our results explain, at least in part, why measures to prevent rehospitalisation have had only a limited impact on the readmission rate, and that successful programs must address multiple aspects of patient care \[[@pone.0233457.ref026], [@pone.0233457.ref030]\].

Disease management programs are advocated in chronic conditions such as HF or COPD after discharge to reduce the readmission rate \[[@pone.0233457.ref034]--[@pone.0233457.ref036]\]. Although there is no uniform way to provide managed care, the majority of such programs improve outcome as shown in several meta-analyses \[[@pone.0233457.ref037]--[@pone.0233457.ref039]\]. The rather broad approach to care of these programs might result in reduction of readmission not only due to the index disease. The clustering of diseases with some clinical validity found in our analysis might allow such assumption. This notion remains speculative, however, until properly tested.

Although the spectrum of causes for readmissions was broad, independently of the cause of the initial admission, there are some conditions that were more common. Thus, myocardial infarction or atrial fibrillation may lead to HF, (treatment of) HF may cause renal failure, and patients with COPD are more susceptible to acquire pneumonia. There were, however, causes that were seen in basically all conditions. Many patients had infections as cause of readmission, in line with previous reports \[[@pone.0233457.ref028]\]. It suggests that such patients are vulnerable early after discharge to acquire infectious diseases or infections may be acquired during hospitalisation (e.g. urinary tract infections due to urine catheters; hospital acquired pneumonia). Additionally, the susceptibility of these patients may be higher than during more stable conditions. Using sufficient hygiene measures such infections might in part be preventable if the general awareness is improved. Education of patients and their families about the increased risk of infection may also be important to aid rapid diagnosis and treatment.

Another important readmission group is related to complications of medical procedures or devices. Although it is not well investigated to what extent such complications are preventable in the setting of chronic conditions, it may be worthwhile to specifically investigate such complications and to test preventive measures to reduce the number. Often, such measures are only taken in the context of surgery and/or invasive procedures, but not as a general routine in patients with chronic conditions.

There was a small, but significant trend for less readmissions with the same condition as the index hospitalisation over time. The aging population and the fact that comorbidities are increasingly frequent at higher age may be accountable for this finding. Age and comorbidities are included in the regression equation as well, which may highlight this, but may have diminished the overtime effect. Therefore, we may expect that the complexity of patients admitted with chronic conditions is increasing in the future as the population ages further. It may also be explained as less complex procedures, and less severe conditions, are treated more in the outpatient setting. Therefore, the increasing complexity of hospitalised patients needs to be considered for future planning of hospital care of chronic diseases.

Limitations {#sec009}
-----------

There are several limitations to our study. Importantly, we used administrative data, capturing only what was coded. Coding is not uniform and may vary depending on diagnosis related group, degree of in-hospital testing, national reimbursement incentives, physician and coder training and institutional variation \[[@pone.0233457.ref040], [@pone.0233457.ref041]\]. Some of these factors may explain why patients in the USA had a higher comorbidity score although they were younger and had a shorter LOS. The higher comorbidities in US patients could also reflect issues of access and late presentation \[[@pone.0233457.ref042]\]. Direct comparison between countries, and also between institutions, regarding the absolute burden of disease is not possible. Also, risk adjustment considering all factors influencing readmissions is limited. However, the purpose of this study was to investigate the associations between index hospitalisation and readmission. As this only relates to the primary diagnosis, coding has a much lower impact. Moreover, the aim was to investigate the global picture of the problem, which is not significantly influenced by the limitation of coding. We did not compare single institutions with each other due to reasons of confidentiality given the limited number of participating hospitals, particularly in continental Europe. Administrative models may have limited discriminatory abilities, which raises concerns about the ability to standardise risk across hospitals to fairly compare hospital performance \[[@pone.0233457.ref016]\]. Our data suggest that previously insufficiently recognised factors related to the complexity of multimorbid patients need to be included to improve risk prediction and adjustment.

We included conditions that present with acute events (i.e. AMI, pneumonia, stroke) but are usually caused by a chronic underlying disease. Including these conditions might have influenced our results. However, readmission pattern of them were in line with the other more chronic conditions, supporting the assumption that the readmissions were mainly influenced by the underlying chronic condition rather than the acute event.

In addition, participating hospitals are academic centres and focus may differ between centres. Therefore, there may be an imbalance in the patient population and differences in the spectrum of patients in centres that did not participate. Also, readmission to a different hospital could not be recorded. Therefore, the true readmission rate is likely even higher than reported here although the disease specific readmission rates may be similar to those reported in the past (for example 7 vs 5% for heart failure) \[[@pone.0233457.ref043]\]. It might be speculated that readmission due to other causes than the initial admission is more likely to be treated in another hospital than the index admission and the absolute values must be interpreted with caution. Nevertheless, the consequence of these two factors would be an even higher readmission rate and a higher proportion of causes different than the initial admission, even more strongly supporting the conclusion of our study.

Conclusions {#sec010}
===========

Readmissions within 30 days after discharge are very common in patients with chronic conditions. These readmissions are, in more than 50% of patients, related to a different cause than the initial hospitalisation. Therefore, this study has significant implications, for clinicians, the hospital administrators and for policy makers. It highlights the importance of a global approach to the treatment and management of patients with chronic conditions. Focus on the chronic condition and the circumstances that led to the hospitalisation is not sufficient, and additional measures based on a more holistic approach to the individual patient should be taken to significantly reduce readmissions.

Supporting information {#sec011}
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Universitair ziekenhuis Leuven Leuven Belgium +32 16 332211 www.uzleuven.be/en

Aalborg UH Aalborg Denmark +45 97 666000 aalborguh.rn.dk/service/english
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Academisch Ziekenhuis Maastricht Maastricht The Netherlands +31 43 3876543 www.mumc.nl
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Hospital of the University of Pennsylvania Philadelphia USA +1 215 6624000 [www.pennmedicine.org](http://www.pennmedicine.org)
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"Figure 5 Link between original condition of admission (left side) and cause of readmission (right side) for each chronic condition. Figure B provides information about all other causes in figure A. These figures (Supporting information: Interacting Figures 4A and 4B) can be found online by clicking on the figures to provide a dynamic depiction of the different causes of readmission for each chronic condition"

In addition, we provided the following information at the end of the manuscript:

"Supplementary table 1: List of participating centres

Supplementary table 2: ICD 9 and ICD 10 codes for chronic conditions

Supplementary figures 5A and 5B: Link between original condition of admission (left side) and cause of readmission (right side) for each chronic condition. Figure B provides information about all other causes in figure A. Interactive online figures to provide a dynamic depiction of the different causes of readmission for each chronic condition"

Comments to comments by the reviewers

Reviewer \#1:

The study is relevant, interesting and well written. I think this paper has the ability for a better understanding of the treatment and management of patients with chronic conditions and the described high rate of about 17% of readmissions. The conclusions could be strengthened. However, the present study is significantly limited by the administrative nature of the data, the lack of robust risk adjustment and the imbalances in the patient population.

We would like to thank the reviewer for carefully reading our manuscript and to provide positive feedback on it.

We agree with the reviewer that the study has important limitations that we also addressed in part in the limitation section of the original submission. We now added the fact that risk adjustment was limited and that there may be an imbalance in the patient population. This is inevitable to administrative data. The advantage of administrative data is that there is no preselection of patients, which is inevitable to most registries. For the purpose of the study, we are convinced that administrative data are useful.

There are some major concerns and limitations which have to be to addressed:

\- The authors should clarify whether the identified ICD codes were main or secondary diagnoses for readmission of the patients. This fact could potentially bias the observed findings.

We agree with the reviewer. This is why we only used main diagnosis for readmission of patients to keep the potential bias as small as possible. We are aware that the coding may be subjective and not homogenous across all centres. This is addressed in the limitation section of the manuscript.

\- Why did the authors choose the 30 days as time point of emergency readmission?

To some extent, this is obviously arbitrary. However, the reason for this is mainly twofold: a) reimbursement policy in the USA is related to the 30-day readmission rate. The result of this fact is that 30-day readmission is often used in publications, which makes comparison more accurate; b) we wanted to avoid interference with new diseases that develop over time to really be able to focus on readmissions related to the initial diagnosis. We did not include this in the revised manuscript as we do not think that this is a crucial part for the understanding. However, if the editor feels that we should add a short paragraph to highlight these thoughts, we are certainly willing to do so.

\- The authors should stratify their findings concerning AMI as reason of readmission in the subtypes of AMI and by OPS codes for coronary interventions. These findings should also be incorporated in the rates of in-hospital mortality and might show differences over the time and by area (country).

Unfortunately, this information is not available with sufficient accuracy. Due to countries having different coding versions, the coding is not sufficient across all countries and sites for this analysis. This is an important reason why we did not split diagnoses / readmissions in further details. Moreover, it would not change the frequency of readmissions due to causes other than the index event. Thus, the main message of the study is not influenced by this. Still, we agree with the reviewer that this would be interesting in a study that specifically addresses the issues of readmissions in AMI patients. However, this is beyond the scope of this study.

\- Table 4 shows the calculated odds-ratios of regression for probability of readmission with the same condition as initial hospitalisation. The authors should adjust the findings i.e. by area (country), length of stay and year of admission.

We agree with the reviewer that this is interesting, which is why we did the multivariable regression analysis as depicted in table 4. Thus, the odds ratios provided are adjusted by all the variables included. Obviously, this was not clear which is why we added that the table contains the results of multivariable regression.

Reviewer \#2:

The issue of readmission rate in chronic disease is of outmost social and economic importance, but it has been often regarded from a disease-specific point of view. The Authors should be commended for their attempt to provide a picture of the possible paths patients with major chronic conditions often follow, using a huge amount of administrative data from all over the world.

We would like to thank the reviewer for his/her positive comment on our study.

While of interest, the value of the findings of the paper is limited from some major methodological issues, as reported below in details.

Major points

\- The Authors state that they "included two acute conditions, i.e. AMI and bacterial pneumonia". Indeed, stroke (acute?!) was also considered in the analysis. Although they were apparently included as they underly other chronic conditions, the Reviewer is rather concerned about this choice.

We agree with the reviewer that stroke is also an acute event, based on an underlying chronic disease. We changed this accordingly in the revised manuscript.

Moreover, we understand the concern by the reviewer. In fact, we had some discussion about this point when designing the analysis. We decided to do so as we aimed to provide a broad picture of readmission of important different chronic diseases and that the underlying disease is most important for them. Also the other included conditions usually have acute events that lead to hospitalisation (e.g. acute decompensation of heart failure or CODP, occurrence of atrial fibrillation). In fact, the readmission rate of these three acute conditions were in line with the other conditions, supporting our choice. Therefore, we did not change the diseases included in the analysis. Nevertheless, we included the following paragraph to the limitation section:

"We included conditions that present with acute events (i.e. AMI, pneumonia, stroke) but are usually caused by a chronic underlying disease. Including these conditions might have influenced our results. However, readmission pattern of them were in line with the other more chronic conditions, supporting the assumption that the readmissions were mainly influenced by the underlying chronic condition rather than the acute event."

\- Only readmissions at the same hospital could be recorded. Although the disease specific readmission rates are similar to those reported in the past (for example 7 vs 5% for heart failure, Fudim M et al. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2018;20:304-314), the whole number of readmission may have been significantly underestimated, especially as concerns those caused by different diseases (as patients may have been referred to different specialized hospitals).

We fully agree with the reviewer which is why we included this discussion point in the original limitation section. In addition, we added the comparison with heart failure as an example as suggested by the reviewer.

\- Administrative and reimbursement issues may have significantly influenced the attribution of the readmission cause, thus possibly biasing the Authors' findings.

We fully agree with the reviewer. This is why we mention this point as our first limitation to our study. As also highlighted in one of the points raised by reviewer \#1, there are pros and cons for the use of administrative data for this kind of analyses. For the purpose of our study, we are convinced that the inclusion of all cases of a specific hospital is an important pro, allowing the conclusions made.

\- How was time to first readmission related to the readmission cause?

This is an interesting point. In fact, the time to readmission was exactly the same if comparing similar or different cause of readmission overall. There were small differences between the different original conditions. Due to the large number of patients, they obviously are all statistically significantly different, but of clinical relevance, only two are meaningful. We added this information to the manuscript in a separate paragraph of the Results section and added a figure (new figure 4).

Minor points

\- How do the Authors explain their observation that readmission rated have not changed significantly along the whole study period for most of the chronic conditions they have considered?

We tend to disagree with the conclusion by the reviewer that there were no changes over time. In fact, there was a significant reduction in admission due to the same condition over time (1.3% per year) as indicated in table 4. As discussed, we hypothesise that this is related to the increase in age / complexity of chronic diseases over time.

\- Discussion should be shortened and focused on the main findings of the study.

We agree in part with the reviewer and have shorten the discussion. We are also aware of the fact that our data are not sufficiently in depth to address all questions related to the topic. In order to stimulate the discussion and additional research in the field -- both to better understand and to prevent readmissions -- we deliberately discussed some issues where our results are more hypothesis generating than providing clear evidence.

Reviewer \#3:

Thank you for the opportunity to review this manuscript. It explored causes of admission and readmission in a unique population of multiple academic centers across the world. In a type of consortium 20+ centers have pooled administrative data for purposes of quality improvement research. IN this analysis the researchers found that in most cases the cause of readmission is different from the cause of admission the first time around. These findings have been previously described in a variable type of cohorts including administrative databases and clinical trial cohorts (see my last comment). Nevertheless this data remains very important and only underlines the need for a more "holistic" patient care (as the authors called it).

We would like to thank the reviewer for the positive comment on our study.

Comments:

\- This study encompasses multiple countries. US policy on readmission reduction was cited but what about other countries? Do they have comparable initiatives?

Although each healthcare system aims to reduce readmission rates, the US policy in this regard is rather unique. This is why we focused on discussing this in our manuscript. Given the fact that reduction in the length of the discussion is suggested by this and another reviewer, we have not extended our discussion in this point.

\- I am not sure I follow the difference between ICD and CCS. Aka Table 1 and 2.

The ICD code defines diseases in more detail, where as the CCS summarises diseases in groups. It is referenced in the paper (see Methods section, ref 17)

\- It is important to understand where the ICD code for the primary diagnosis was derived from. Did the ICD code get obtained from the billing information, discharge notes etc? Only the code I the first position was used?

Administrative dataset contain data that are used for national registers and are obtained from discharge notes. As mentioned in the manuscript, only the main diagnosis was used.

\- Found the amount of information provide in the figures to be somewhat overwhelming.

We understand this notion by the reviewer. However, we are convinced that this is a strength of the manuscript as information is available if readers are interested in the details of our findings. This is why we did not reduce it.

\- Abbreviations in all tables and figures need to be presented in legends.

We agree with the reviewer and changed this accordingly.

\- Information in the discussion section is repetitive. Reduce repetition and reduce in length.

We agree in part with the reviewer and have shorten the discussion, particularly to avoid repetition unless required to understand the context of the according paragraph. We are also aware of the fact that our data are not sufficiently in depth to address all questions related to the topic. In order to stimulate the discussion and additional research in the field -- both to better understand and to prevent readmissions -- we deliberately discussed some issues where our results are more hypothesis generating than providing clear evidence.

\- Given that HF is a major contributor to the admission and readmission consider to discuss some of the already published literature on this topic. PMID: 27133201 and PMID: 29082629.

We agree with the reviewer that HF is an important chronic condition. As also suggested by one of the other reviewers, we added one of the two suggested references to the manuscript, mentioning HF as example for comparison with our results.
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